Molecular Targets and Nano-Technological Approaches in the Treatment of Hepatic Carcinoma.

IF 2.3 4区 医学 Q3 ONCOLOGY
Trilochan Satapathy, Maneesh Kumar Diwakar
{"title":"Molecular Targets and Nano-Technological Approaches in the Treatment of Hepatic Carcinoma.","authors":"Trilochan Satapathy, Maneesh Kumar Diwakar","doi":"10.2174/0115680096336494240915164019","DOIUrl":null,"url":null,"abstract":"<p><p>Liver cancer is a leading cause of cancer-related mortality, with about one million people losing their lives each year. The disease becomes even more dangerous when tumors cannot be removed through surgery. Globally, hepatocellular carcinoma (HCC) ranks third in terms of fatality rates among liver cancers. It is also the most frequent type of liver cancer. Due to the high mortality rate associated with this malignancy, it is a hotspot for researchers looking to improve treatment methods. Nanotechnology plays an important part in these at-tempts. Various types of nanoparticles (NPs) have been investigated for their ability to fight liver cancer. NPs are a vast class of materials. The article details the efforts made to include inorganic NPs, such as silver, gold, metal oxide, platinum, calcium, selenium, and other un-common materials into drug delivery systems (DDS) for therapeutic, carrier, or imaging pur-poses. This review discusses the function of carbon-based NPs in DDS for the treatment of liver cancer, including polymeric, polysaccharide, lipid, and carbon dot NPs, all of which have been extensively researched for this purpose. The purpose of this review is to provide a con-cise overview of recent developments in the field of HCC based on current research and clini-cal diagnosis and treatment guidelines. Further goals include elucidating the current state of nanomaterials research, its limitations, and the potential for future advancements in the field, as well as the use of nanotechnology in the detection and treatment of HCC.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096336494240915164019","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Liver cancer is a leading cause of cancer-related mortality, with about one million people losing their lives each year. The disease becomes even more dangerous when tumors cannot be removed through surgery. Globally, hepatocellular carcinoma (HCC) ranks third in terms of fatality rates among liver cancers. It is also the most frequent type of liver cancer. Due to the high mortality rate associated with this malignancy, it is a hotspot for researchers looking to improve treatment methods. Nanotechnology plays an important part in these at-tempts. Various types of nanoparticles (NPs) have been investigated for their ability to fight liver cancer. NPs are a vast class of materials. The article details the efforts made to include inorganic NPs, such as silver, gold, metal oxide, platinum, calcium, selenium, and other un-common materials into drug delivery systems (DDS) for therapeutic, carrier, or imaging pur-poses. This review discusses the function of carbon-based NPs in DDS for the treatment of liver cancer, including polymeric, polysaccharide, lipid, and carbon dot NPs, all of which have been extensively researched for this purpose. The purpose of this review is to provide a con-cise overview of recent developments in the field of HCC based on current research and clini-cal diagnosis and treatment guidelines. Further goals include elucidating the current state of nanomaterials research, its limitations, and the potential for future advancements in the field, as well as the use of nanotechnology in the detection and treatment of HCC.

治疗肝癌的分子靶点和纳米技术方法。
肝癌是导致癌症相关死亡的主要原因,每年约有 100 万人因此丧生。如果肿瘤无法通过手术切除,这种疾病就会变得更加危险。在全球范围内,肝细胞癌(HCC)的致死率在肝癌中排名第三。它也是最常见的肝癌类型。由于这种恶性肿瘤的死亡率很高,因此成为研究人员寻求改进治疗方法的热点。纳米技术在这些尝试中扮演着重要角色。研究人员对各种类型的纳米粒子(NPs)进行了研究,以了解它们抗击肝癌的能力。纳米粒子是一类种类繁多的材料。文章详细介绍了将无机纳米粒子(如银、金、金属氧化物、铂、钙、硒和其他不常见的材料)纳入药物输送系统(DDS)以达到治疗、载体或成像目的的努力。本综述讨论了碳基 NPs 在 DDS 中用于治疗肝癌的功能,包括聚合物、多糖、脂质和碳点 NPs,所有这些都已为此目的进行了广泛研究。本综述的目的是根据目前的研究和临床诊断与治疗指南,对 HCC 领域的最新进展进行准确概述。进一步的目标包括阐明纳米材料研究的现状、局限性和该领域未来发展的潜力,以及纳米技术在检测和治疗 HCC 中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current cancer drug targets
Current cancer drug targets 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
105
审稿时长
1 months
期刊介绍: Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信